aplastic anemia | Page 35 | Aplastic Anemia & MDS International Foundation

aplastic anemia

Stem Cell Transplant from Unrelated Donor in Patients with Severe Aplastic Anemia: Indications, Donor Selection, Conditioning, GVHD Prophylaxis

Author(s): 
Iori AP, Scalzulli E, Lombardi L, Torelli GF, Barberi W
Primary Author: 
Iori AP
Journal Title: 
Curr Drug Targets
Original Publication Date: 
Feb 2015

Acquired Severe

Bone Marrow Diseases: 

Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia

Author(s): 
Cutler C
Primary Author: 
Cutler C
Journal Title: 
Hematology Am Soc Hematol Educ Program
Original Publication Date: 
Dec 2014

Allogeneic hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) is a potentially curative procedure, but is associated with a significant risk of morbidity and mortality. With the recent approval of disease-modifying agents, the appropriate timing of allogeneic HSCT needs to be addressed. Similarly, the optimal use of these disease-modifying agents before HSCT needs to be determined. In

Bone Marrow Diseases: 

Pediatric aplastic anemia and refractory cytopenia: A retrospective analysis assessing outcomes and histomorphologic predictors

Author(s): 
Forester C, Sartain S, Guo D, Harris MH, Weinberg OK, Fleming MD, London WB, Williams DA, Hofmann I
Primary Author: 
Forester C
Journal Title: 
Am J Hematol
Original Publication Date: 
Jan 2015

Pediatric acquired

Bone Marrow Diseases: 

Current outcome of HLA identical sibling vs. unrelated donor transplants in severe aplastic anemia: an EBMT analysis

Author(s): 
Bacigalupo A, Socié G, Hamladji RM, Aljurf M, Maschan A, Kyrcz-Krzemien S, Cybicka A, Sengelov H, Unal A, Beelen D, Locasciulli A, Dufour C, Passweg JR, Oneto R, Signori A, Marsh JC
Primary Author: 
Bacigalupo A
Journal Title: 
Haematologica
Original Publication Date: 
Jan 2015

We have analyzed 1448 patients with acquired

Bone Marrow Diseases: 

Aplastic Anemia: Alternative Immunosuppressive Treatments and Eltrombopag. A report from the 2014 EBMT Educational Meeting from the Severe Aplastic Anaemia and Infectious Diseases Working Parties

Author(s): 
Risitano AM
Primary Author: 
Risitano AM
Journal Title: 
Curr Drug Targets
Original Publication Date: 
Jan 2015

Acquired idiopathic AA is the most typical form of immune-mediated bone marrow failure; the standard treatment of AA for patients who lack a transplant option is immunosuppressive treatment (IST). The standard IST regimen is horse anti-thymocyte globuline (h-ATG) combined with

Bone Marrow Diseases: